≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Cerebral oedema

DOID EFO Endpoint Browser PheWeb

G6_CEROEDEMA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G93.6
  • Hospital discharge: ICD-9 — 3485
  • Cause of death: ICD-10 — G93.6
  • Cause of death: ICD-9 — 3485

2 out of 7 registries used, show all original rules.

78

4. Check minimum number of events

None

78

5. Include endpoints

None

78

6. Filter based on genotype QC (FinnGen only)

73

Control definitions (FinnGen only)

Control exclude
G6_OTHNEU

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
G93
Name in latin
Oedema cerebri

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 918 430 478
Only index persons 515 232 283
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 50.49 52.34 48.62
Only index persons 51.71 52.78 50.83

-FinnGen-

Key figures

All Female Male
Number of individuals 73 38 35
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 56.02 55.98 56.06

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
78
Matched controls
780
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.6
ICD-10 Finland
Cerebral oedema
+∞
106.7
76
*
N03AX14
ATC
levetiracetam; systemic
58.7
28.0
32
9
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.6
27.2
30
32
AA1AD
NOMESCO Finland
CT of head and brain
9.7
23.0
51
127
130
Kela drug reimbursment
Malignant tumour
10.0
18.7
26
37
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
42.8
18.2
22
7
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
23.8
17.6
25
15
H02AB02
ATC
dexamethasone; systemic
7.9
17.0
31
60
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
53.3
14.8
17
*
L01AX03
ATC
temozolomide; systemic
66.0
14.4
16
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.3
13.5
31
74
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
61.0
13.4
15
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
6.1
12.2
28
66
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.0
12.0
28
67
N03AX18
ATC
lacosamide; systemic
76.8
12.0
13
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
30.7
10.2
13
5
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.9
9.4
20
43
R56.8
ICD-10 Finland
Other and unspecified convulsions
10.8
9.4
18
21
AAK80
NOMESCO Finland
Partial excision of skull cap
+∞
8.5
8
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.4
8.0
12
8
G40.9
ICD-10 Finland
Epilepsy, unspecified
17.4
8.0
12
8
WX882
NOMESCO Finland
High dependency care
13.9
7.9
13
11
A04AA01
ATC
ondansetron; systemic, rectal
7.3
7.9
19
33
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
88.1
7.6
8
*
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
88.1
7.6
8
*
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
88.1
7.6
8
*
WF002
NOMESCO Finland
Radical radiotherapy
9.5
7.5
15
19
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
+∞
7.4
7
*
AAK00
NOMESCO Finland
Cranioplasty
+∞
7.4
7
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
7.4
7
*
AAF00
NOMESCO Finland
Ventriculostomy
+∞
7.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.9
7.3
28
97
A03FA01
ATC
metoclopramide; systemic, rectal
3.9
7.3
29
103
ZXC95
NOMESCO Finland
Use of surgical navigator
25.1
6.8
9
*
WX872
NOMESCO Finland
Intensive care
11.6
6.8
12
12
I69.0
ICD-10 Finland
Sequelae of subarachnoid haemorrhage
75.8
6.5
7
*
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
75.8
6.5
7
*
R51.80
ICD-10 Finland
Headache
3.9
6.5
24
80
A04AA02
ATC
granisetron; systemic, transdermal
6.6
6.1
15
27

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.5e+00
2.2e+00
3.1e+00
1.0e+50
4.4e+00
—
—
cases:32.89%
controls:9.74%
cases:31.58%
controls:4.74%
cases:17.11%
controls:0.92%
cases:32.89%
controls:0.00%
cases:40.32%
controls:0.79%
—
—
—
—
25
74
51
686
24
36
52
724
13
7
63
753
25
0
51
760
25
6
37
754
—
—
Inpatient Hospital
21 [8717]
3.5e-01
1.5e+00
3.2e+00
1.0e+50
4.3e+00
—
—
cases:38.16%
controls:30.39%
cases:28.95%
controls:8.03%
cases:14.47%
controls:0.66%
cases:31.58%
controls:0.00%
cases:37.10%
controls:0.79%
—
—
—
—
29
231
47
529
22
61
54
699
11
5
65
755
24
0
52
760
23
6
39
754
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-1.7e-01
7.5e-02
1.4e+00
5.0e+00
2.5e+00
—
—
cases:47.37%
controls:51.71%
cases:44.74%
controls:42.89%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.66%
—
—
—
—
36
393
40
367
34
326
42
434
26
87
50
673
39
5
37
755
36
81
26
679
—
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-1.7e-01
8.0e-02
1.4e+00
5.0e+00
2.5e+00
—
—
cases:47.37%
controls:51.58%
cases:44.74%
controls:42.76%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.66%
—
—
—
—
36
392
40
368
34
325
42
435
26
87
50
673
39
5
37
755
36
81
26
679
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.7e-01
7.5e-02
1.4e+00
5.0e+00
2.5e+00
—
—
cases:47.37%
controls:51.58%
cases:44.74%
controls:42.89%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.66%
—
—
—
—
36
392
40
368
34
326
42
434
26
87
50
673
39
5
37
755
36
81
26
679
—
—
MCH [Entitic mass]
28539-5 [3035941]
-1.7e-01
7.5e-02
1.4e+00
5.0e+00
2.5e+00
—
—
cases:47.37%
controls:51.58%
cases:44.74%
controls:42.89%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.66%
—
—
—
—
36
392
40
368
34
326
42
434
26
87
50
673
39
5
37
755
36
81
26
679
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-1.7e-01
7.5e-02
1.4e+00
5.0e+00
2.5e+00
—
—
cases:47.37%
controls:51.58%
cases:44.74%
controls:42.89%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.66%
—
—
—
—
36
392
40
368
34
326
42
434
26
87
50
673
39
5
37
755
36
81
26
679
—
—
Platelets [#/volume] in Blood
26515-7 [3007461]
-1.6e-01
8.6e-02
1.4e+00
5.0e+00
2.4e+00
—
—
cases:47.37%
controls:51.45%
cases:44.74%
controls:42.63%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.79%
—
—
—
—
36
391
40
369
34
324
42
436
26
87
50
673
39
5
37
755
36
82
26
678
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.7e-01
7.5e-02
1.4e+00
5.0e+00
2.4e+00
—
—
cases:47.37%
controls:51.71%
cases:44.74%
controls:42.89%
cases:34.21%
controls:11.45%
cases:51.32%
controls:0.66%
cases:58.06%
controls:10.79%
—
—
—
—
36
393
40
367
34
326
42
434
26
87
50
673
39
5
37
755
36
82
26
678
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
9.5e-01
1.5e+00
2.3e+00
—
2.9e+00
—
—
cases:26.32%
controls:12.11%
cases:26.32%
controls:7.37%
cases:14.47%
controls:1.58%
—
—
cases:19.35%
controls:1.32%
—
—
—
—
20
92
56
668
20
56
56
704
11
12
65
748
—
12
10
50
750
—
—
Medical Oncology
90 [38004507]
8.0e-01
1.9e+00
2.7e+00
—
3.0e+00
—
—
cases:9.21%
controls:4.34%
cases:21.05%
controls:3.68%
cases:17.11%
controls:1.32%
—
—
cases:20.97%
controls:1.32%
—
—
—
—
7
33
69
727
16
28
60
732
13
10
63
750
—
13
10
49
750
—
—
Laboratory Visit
OMOP4822461 [32036]
-1.8e-01
5.8e-02
1.0e+00
4.6e+00
1.8e+00
—
—
cases:52.63%
controls:56.97%
cases:53.95%
controls:52.50%
cases:38.16%
controls:18.03%
cases:52.63%
controls:1.05%
cases:58.06%
controls:18.55%
—
—
—
—
40
433
36
327
41
399
35
361
29
137
47
623
40
8
36
752
36
141
26
619
—
—
General Practice
1 [38004446]
-1.9e-01
1.3e+00
2.5e+00
—
3.4e+00
—
—
cases:10.53%
controls:12.50%
cases:17.11%
controls:5.13%
cases:9.21%
controls:0.79%
—
—
cases:16.13%
controls:0.66%
—
—
—
—
8
95
68
665
13
39
63
721
7
6
69
754
—
10
5
52
755
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.3e-01
1.5e+00
2.1e+00
1.0e+50
3.3e+00
—
—
cases:22.37%
controls:15.79%
cases:26.32%
controls:7.37%
cases:18.42%
controls:2.63%
cases:7.89%
controls:0.00%
cases:30.65%
controls:1.58%
—
—
—
—
17
120
59
640
20
56
56
704
14
20
62
740
6
0
70
760
19
12
43
748
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
8.8e-01
1.5e+00
2.2e+00
—
3.1e+00
—
—
cases:23.68%
controls:11.45%
cases:25.00%
controls:6.71%
cases:10.53%
controls:1.32%
—
—
cases:19.35%
controls:1.05%
—
—
—
—
18
87
58
673
19
51
57
709
8
10
68
750
—
12
8
50
752
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.7e-01
6.2e-01
1.9e+00
—
3.4e+00
—
—
cases:43.42%
controls:39.21%
cases:36.84%
controls:23.95%
cases:30.26%
controls:6.05%
—
—
cases:56.45%
controls:4.21%
—
—
—
—
33
298
43
462
28
182
48
578
23
46
53
714
—
35
32
27
728
—
—
Outpatient Hospital
22 [8756]
4.3e-01
1.5e+00
—
1.0e+50
3.8e+00
—
—
cases:34.21%
controls:25.26%
cases:21.05%
controls:5.79%
—
—
cases:19.74%
controls:0.00%
cases:29.03%
controls:0.92%
—
—
—
—
26
192
50
568
16
44
60
716
—
15
0
61
760
18
7
44
753
—
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.9e-01
1.8e+00
3.2e+00
1.0e+50
—
—
—
cases:28.95%
controls:15.66%
cases:31.58%
controls:6.97%
cases:17.11%
controls:0.79%
cases:34.21%
controls:0.00%
—
—
—
—
—
—
22
119
54
641
24
53
52
707
13
6
63
754
26
0
50
760
—
—
—
Internal Medicine
11 [38004456]
4.1e-01
9.7e-01
2.4e+00
—
2.6e+00
—
—
cases:28.95%
controls:21.32%
cases:19.74%
controls:8.55%
cases:14.47%
controls:1.45%
—
—
cases:8.06%
controls:0.66%
—
—
—
—
22
162
54
598
15
65
61
695
11
11
65
749
—
5
5
57
755
—
—
Neurosurgery
14 [38004459]
1.8e+00
3.2e+00
—
1.0e+50
—
—
—
cases:14.47%
controls:2.63%
cases:22.37%
controls:1.18%
—
—
cases:17.11%
controls:0.00%
—
—
—
—
—
—
11
20
65
740
17
9
59
751
—
13
0
63
760
—
—
—
Emergency Room Visit
ER [9203]
3.4e-01
1.7e+00
3.3e+00
—
—
—
—
cases:42.11%
controls:34.08%
cases:36.84%
controls:9.74%
cases:22.37%
controls:1.05%
—
—
—
—
—
—
—
—
32
259
44
501
28
74
48
686
17
8
59
752
—
—
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
7.5e-02
4.2e-01
1.6e+00
—
3.0e+00
—
—
cases:43.42%
controls:41.58%
cases:40.79%
controls:31.18%
cases:30.26%
controls:7.76%
—
—
cases:56.45%
controls:6.05%
—
—
—
—
33
316
43
444
31
237
45
523
23
59
53
701
—
35
46
27
714
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
8.6e-02
4.1e-01
1.6e+00
—
3.0e+00
—
—
cases:43.42%
controls:41.32%
cases:40.79%
controls:31.32%
cases:30.26%
controls:7.76%
—
—
cases:56.45%
controls:6.18%
—
—
—
—
33
314
43
446
31
238
45
522
23
59
53
701
—
35
47
27
713
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.2e-01
1.2e+00
2.0e+00
—
3.4e+00
—
—
cases:18.42%
controls:11.84%
cases:17.11%
controls:5.92%
cases:6.58%
controls:0.92%
—
—
cases:19.35%
controls:0.79%
—
—
—
—
14
90
62
670
13
45
63
715
5
7
71
753
—
12
6
50
754
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.5e+00
2.9e+00
—
1.0e+50
1.0e+50
—
—
cases:13.16%
controls:3.16%
cases:13.16%
controls:0.79%
—
—
cases:9.21%
controls:0.00%
cases:9.68%
controls:0.00%
—
—
—
—
10
24
66
736
10
6
66
754
—
7
0
69
760
6
0
56
760
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
-6.9e-02
7.1e-01
1.9e+00
1.0e+50
2.4e+00
—
—
cases:25.00%
controls:26.32%
cases:30.26%
controls:17.63%
cases:22.37%
controls:3.95%
cases:7.89%
controls:0.00%
cases:29.03%
controls:3.42%
—
—
—
—
19
200
57
560
23
134
53
626
17
30
59
730
6
0
70
760
18
26
44
734
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
7.9e-01
1.5e+00
1.1e+00
—
2.6e+00
—
—
cases:22.37%
controls:11.58%
cases:21.05%
controls:5.66%
cases:6.58%
controls:2.24%
—
—
cases:20.97%
controls:1.84%
—
—
—
—
17
88
59
672
16
43
60
717
5
17
71
743
—
13
14
49
746
—
—
Infiltration anesthesia
WX110 [2001310767]
-5.2e-02
1.3e+00
—
1.0e+50
2.8e+00
—
—
cases:22.37%
controls:23.29%
cases:22.37%
controls:7.50%
—
—
cases:7.89%
controls:0.00%
cases:9.68%
controls:0.66%
—
—
—
—
17
177
59
583
17
57
59
703
—
6
0
70
760
6
5
56
755
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-7.4e-02
2.5e-01
1.5e+00
1.0e+50
2.5e+00
—
—
cases:44.74%
controls:46.58%
cases:42.11%
controls:36.05%
cases:32.89%
controls:10.00%
cases:52.63%
controls:0.00%
cases:54.84%
controls:8.68%
—
—
—
—
34
354
42
406
32
274
44
486
25
76
51
684
40
0
36
760
34
66
28
694
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
0.0e+00
2.9e-01
1.6e+00
1.0e+50
2.4e+00
—
—
cases:34.21%
controls:34.21%
cases:32.89%
controls:26.84%
cases:27.63%
controls:7.24%
cases:36.84%
controls:0.00%
cases:43.55%
controls:6.58%
—
—
—
—
26
260
50
500
25
204
51
556
21
55
55
705
28
0
48
760
27
50
35
710
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
1.1e-01
1.3e+00
8.8e-01
—
2.7e+00
—
—
cases:23.68%
controls:21.71%
cases:30.26%
controls:10.79%
cases:7.89%
controls:3.42%
—
—
cases:22.58%
controls:1.97%
—
—
—
—
18
165
58
595
23
82
53
678
6
26
70
734
—
14
15
48
745
—
—
Emergency Room and Inpatient Visit
ERIP [262]
8.0e-01
1.5e+00
2.4e+00
1.0e+50
—
—
—
cases:9.21%
controls:4.34%
cases:13.16%
controls:3.16%
cases:7.89%
controls:0.79%
cases:26.32%
controls:0.00%
—
—
—
—
—
—
7
33
69
727
10
24
66
736
6
6
70
754
20
0
56
760
—
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-1.2e-01
-1.2e-02
1.2e+00
—
2.6e+00
—
—
cases:39.47%
controls:42.37%
cases:30.26%
controls:30.53%
cases:22.37%
controls:7.63%
—
—
cases:50.00%
controls:7.24%
—
—
—
—
30
322
46
438
23
232
53
528
17
58
59
702
—
31
55
31
705
—
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.7e-01
1.3e+00
—
1.0e+50
3.8e+00
—
—
cases:13.16%
controls:7.89%
cases:13.16%
controls:4.08%
—
—
cases:13.16%
controls:0.00%
cases:22.58%
controls:0.66%
—
—
—
—
10
60
66
700
10
31
66
729
—
10
0
66
760
14
5
48
755
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
-4.8e-02
-2.5e-02
1.3e+00
—
2.4e+00
—
—
cases:42.11%
controls:43.29%
cases:28.95%
controls:29.47%
cases:21.05%
controls:6.84%
—
—
cases:37.10%
controls:5.13%
—
—
—
—
32
329
44
431
22
224
54
536
16
52
60
708
—
23
39
39
721
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
9.0e-02
3.6e-01
1.5e+00
—
2.1e+00
—
—
cases:46.05%
controls:43.82%
cases:42.11%
controls:33.68%
cases:26.32%
controls:7.37%
—
—
cases:40.32%
controls:7.63%
—
—
—
—
35
333
41
427
32
256
44
504
20
56
56
704
—
25
58
37
702
—
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-1.1e-01
1.2e-01
1.3e+00
—
2.3e+00
—
—
cases:32.89%
controls:35.39%
cases:31.58%
controls:28.95%
cases:25.00%
controls:8.29%
—
—
cases:45.16%
controls:7.76%
—
—
—
—
25
269
51
491
24
220
52
540
19
63
57
697
—
28
59
34
701
—
—
Bacteria identified in Blood by Culture
600-7 [3023368]
1.3e+00
2.1e+00
—
—
—
—
—
cases:17.11%
controls:5.13%
cases:15.79%
controls:2.24%
—
—
—
—
—
—
—
—
—
—
13
39
63
721
12
17
64
743
—
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.2e-01
8.5e-01
1.6e+00
—
1.7e+00
—
—
cases:25.00%
controls:19.47%
cases:26.32%
controls:13.29%
cases:14.47%
controls:3.16%
—
—
cases:17.74%
controls:3.68%
—
—
—
—
19
148
57
612
20
101
56
659
11
24
65
736
—
11
28
51
732
—
—
Case Management Agency
251B00000X [38004193]
-4.7e-02
1.3e-01
6.6e-01
3.3e+00
7.0e-01
—
—
cases:72.37%
controls:73.29%
cases:68.42%
controls:65.53%
cases:46.05%
controls:30.53%
cases:40.79%
controls:2.37%
cases:45.16%
controls:29.08%
—
—
—
—
55
557
21
203
52
498
24
262
35
232
41
528
31
18
45
742
28
221
34
539
—
—
Emergency Medicine
93 [38004510]
6.1e-01
1.2e+00
2.0e+00
1.0e+50
—
—
—
cases:26.32%
controls:16.32%
cases:22.37%
controls:7.63%
cases:10.53%
controls:1.58%
cases:39.47%
controls:0.00%
—
—
—
—
—
—
20
124
56
636
17
58
59
702
8
12
68
748
30
0
46
760
—
—
—
Immunohistochemistry procedure
117617002 [4035726]
1.6e+00
3.2e+00
—
—
1.0e+50
—
—
cases:7.89%
controls:1.71%
cases:14.47%
controls:0.66%
—
—
—
—
cases:14.52%
controls:0.00%
—
—
—
—
6
13
70
747
11
5
65
755
—
—
9
0
53
760
—
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.2e+00
2.0e+00
—
1.0e+50
—
—
—
cases:19.74%
controls:6.97%
cases:18.42%
controls:2.89%
—
—
cases:26.32%
controls:0.00%
—
—
—
—
—
—
15
53
61
707
14
22
62
738
—
20
0
56
760
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.4e-01
2.8e-01
—
1.0e+50
3.2e+00
—
—
cases:23.68%
controls:21.18%
cases:15.79%
controls:12.37%
—
—
cases:6.58%
controls:0.00%
cases:16.13%
controls:0.79%
—
—
—
—
18
161
58
599
12
94
64
666
—
5
0
71
760
10
6
52
754
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.6e+00
3.1e+00
—
—
1.0e+50
—
—
cases:9.21%
controls:1.97%
cases:13.16%
controls:0.66%
—
—
—
—
cases:16.13%
controls:0.00%
—
—
—
—
7
15
69
745
10
5
66
755
—
—
10
0
52
760
—
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.6e+00
3.1e+00
—
—
1.0e+50
—
—
cases:9.21%
controls:1.97%
cases:13.16%
controls:0.66%
—
—
—
—
cases:16.13%
controls:0.00%
—
—
—
—
7
15
69
745
10
5
66
755
—
—
10
0
52
760
—
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.6e+00
3.1e+00
—
—
1.0e+50
—
—
cases:9.21%
controls:1.97%
cases:13.16%
controls:0.66%
—
—
—
—
cases:16.13%
controls:0.00%
—
—
—
—
7
15
69
745
10
5
66
755
—
—
10
0
52
760
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.5e+00
1.8e+00
—
—
3.1e+00
—
—
cases:11.84%
controls:2.89%
cases:9.21%
controls:1.71%
—
—
—
—
cases:12.90%
controls:0.66%
—
—
—
—
9
22
67
738
7
13
69
747
—
—
8
5
54
755
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
-1.1e-01
2.9e-01
—
—
3.1e+00
—
—
cases:9.21%
controls:10.13%
cases:6.58%
controls:5.00%
—
—
—
—
cases:14.52%
controls:0.79%
—
—
—
—
7
77
69
683
5
38
71
722
—
—
9
6
53
754
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.2e+00
1.2e+00
—
—
2.9e+00
—
—
cases:9.21%
controls:2.89%
cases:7.89%
controls:2.50%
—
—
—
—
cases:11.29%
controls:0.66%
—
—
—
—
7
22
69
738
6
19
70
741
—
—
7
5
55
755
—
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.4e+00
2.9e+00
—
—
1.0e+50
—
—
cases:6.58%
controls:1.71%
cases:10.53%
controls:0.66%
—
—
—
—
cases:8.06%
controls:0.00%
—
—
—
—
5
13
71
747
8
5
68
755
—
—
5
0
57
760
—
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.9e-01
1.1e+00
1.6e+00
—
1.8e+00
—
—
cases:21.05%
controls:15.26%
cases:22.37%
controls:9.08%
cases:7.89%
controls:1.71%
—
—
cases:12.90%
controls:2.37%
—
—
—
—
16
116
60
644
17
69
59
691
6
13
70
747
—
8
18
54
742
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.8e-01
1.0e+00
1.6e+00
—
1.8e+00
—
—
cases:21.05%
controls:15.39%
cases:22.37%
controls:9.21%
cases:7.89%
controls:1.71%
—
—
cases:12.90%
controls:2.37%
—
—
—
—
16
117
60
643
17
70
59
690
6
13
70
747
—
8
18
54
742
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.9e-01
1.0e+00
1.6e+00
—
1.8e+00
—
—
cases:21.05%
controls:15.26%
cases:22.37%
controls:9.21%
cases:7.89%
controls:1.71%
—
—
cases:12.90%
controls:2.37%
—
—
—
—
16
116
60
644
17
70
59
690
6
13
70
747
—
8
18
54
742
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.0e-01
3.6e-01
—
—
2.8e+00
—
—
cases:13.16%
controls:11.05%
cases:9.21%
controls:6.58%
—
—
—
—
cases:9.68%
controls:0.66%
—
—
—
—
10
84
66
676
7
50
69
710
—
—
6
5
56
755
—
—
pH of Urine
2756-5 [3015736]
2.5e-01
5.2e-01
—
—
2.8e+00
—
—
cases:11.84%
controls:9.47%
cases:9.21%
controls:5.66%
—
—
—
—
cases:9.68%
controls:0.66%
—
—
—
—
9
72
67
688
7
43
69
717
—
—
6
5
56
755
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.3e-01
3.4e-01
—
1.0e+50
2.8e+00
—
—
cases:13.16%
controls:11.71%
cases:9.21%
controls:6.71%
—
—
cases:6.58%
controls:0.00%
cases:9.68%
controls:0.66%
—
—
—
—
10
89
66
671
7
51
69
709
—
5
0
71
760
6
5
56
755
—
—
Malignant tumour
130 [2001600128]
2.7e+00
—
—
—
—
—
—
cases:10.53%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
8
6
68
754
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
1.2e+00
2.6e+00
—
—
1.0e+50
—
—
cases:7.89%
controls:2.63%
cases:15.79%
controls:1.32%
—
—
—
—
cases:37.10%
controls:0.00%
—
—
—
—
6
20
70
740
12
10
64
750
—
—
23
0
39
760
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.5e-01
7.5e-01
1.2e+00
—
2.6e+00
—
—
cases:26.32%
controls:20.13%
cases:19.74%
controls:10.39%
cases:7.89%
controls:2.63%
—
—
cases:19.35%
controls:1.71%
—
—
—
—
20
153
56
607
15
79
61
681
6
20
70
740
—
12
13
50
747
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.5e-01
4.7e-01
1.6e+00
—
2.6e+00
—
—
cases:13.16%
controls:11.58%
cases:10.53%
controls:6.84%
cases:6.58%
controls:1.45%
—
—
cases:9.68%
controls:0.79%
—
—
—
—
10
88
66
672
8
52
68
708
5
11
71
749
—
6
6
56
754
—
—
Oncology Clinic/Center
261QX0200X [38004268]
7.9e-01
2.5e+00
—
1.0e+50
1.0e+50
—
—
cases:13.16%
controls:6.45%
cases:17.11%
controls:1.58%
—
—
cases:6.58%
controls:0.00%
cases:9.68%
controls:0.00%
—
—
—
—
10
49
66
711
13
12
63
748
—
5
0
71
760
6
0
56
760
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.5e-01
7.7e-01
1.6e+00
—
2.4e+00
—
—
cases:23.68%
controls:17.89%
cases:18.42%
controls:9.47%
cases:7.89%
controls:1.71%
—
—
cases:12.90%
controls:1.32%
—
—
—
—
18
136
58
624
14
72
62
688
6
13
70
747
—
8
10
54
750
—
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
2.4e+00
—
—
—
—
—
—
—
cases:9.21%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
7
7
69
753
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
1.2e+00
2.4e+00
—
1.0e+50
—
—
—
cases:7.89%
controls:2.50%
cases:6.58%
controls:0.66%
—
—
cases:7.89%
controls:0.00%
—
—
—
—
—
—
6
19
70
741
5
5
71
755
—
6
0
70
760
—
—
—
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
2.3e+00
—
—
—
1.0e+50
—
—
cases:10.53%
controls:1.18%
—
—
—
—
—
—
cases:11.29%
controls:0.00%
—
—
—
—
8
9
68
751
—
—
—
7
0
55
760
—
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.4e+00
2.2e+00
—
—
—
—
—
cases:7.89%
controls:1.97%
cases:9.21%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
6
15
70
745
7
8
69
752
—
—
—
—
—
Gas panel - Venous blood
24339-4 [3000991]
—
2.2e+00
—
—
—
—
—
—
—
cases:7.89%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
6
7
70
753
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
2.2e+00
—
—
—
—
—
—
—
cases:7.89%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
6
7
70
753
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.3e+00
2.2e+00
—
—
—
—
—
cases:11.84%
controls:3.68%
cases:11.84%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
9
28
67
732
9
11
67
749
—
—
—
—
—
Essential (primary) hypertension
I10 [45591453]
1.8e-01
7.1e-01
—
—
2.2e+00
—
—
cases:21.05%
controls:18.29%
cases:17.11%
controls:9.21%
—
—
—
—
cases:14.52%
controls:1.84%
—
—
—
—
16
139
60
621
13
70
63
690
—
—
9
14
53
746
—
—
mometasone
D07AC13 [21602132]
3.5e-01
2.1e+00
—
—
—
—
—
cases:6.58%
controls:4.74%
cases:7.89%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
5
36
71
724
6
8
70
752
—
—
—
—
—
oxycodone; oral, parenteral
N02AA05 [21604260]
1.4e+00
2.1e+00
—
—
—
—
—
cases:6.58%
controls:1.71%
cases:7.89%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
5
13
71
747
6
8
70
752
—
—
—
—
—
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
2.1e+00
—
—
—
—
—
—
cases:10.53%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
8
11
68
749
—
—
—
—
—
—
Inpatient Visit
IP [9201]
8.1e-02
2.0e+00
—
—
—
—
—
cases:9.21%
controls:8.55%
cases:19.74%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
7
65
69
695
15
24
61
736
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
6.6e-01
1.1e+00
1.6e+00
—
2.0e+00
—
—
cases:17.11%
controls:9.61%
cases:18.42%
controls:7.24%
cases:6.58%
controls:1.45%
—
—
cases:12.90%
controls:1.97%
—
—
—
—
13
73
63
687
14
55
62
705
5
11
71
749
—
8
15
54
745
—
—
General anaesthesia
WX402 [2001310806]
—
2.0e+00
—
—
—
—
—
—
—
cases:10.53%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
8
12
68
748
—
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
5.0e-01
1.8e+00
—
—
—
—
—
cases:6.58%
controls:4.08%
cases:14.47%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
5
31
71
729
11
20
65
740
—
—
—
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.6e-01
1.0e+00
1.6e+00
—
1.8e+00
—
—
cases:21.05%
controls:15.66%
cases:22.37%
controls:9.61%
cases:7.89%
controls:1.71%
—
—
cases:12.90%
controls:2.37%
—
—
—
—
16
119
60
641
17
73
59
687
6
13
70
747
—
8
18
54
742
—
—
Office Visit
OMOP4822458 [581477]
3.8e-01
1.8e+00
—
—
—
—
—
cases:11.84%
controls:8.42%
cases:13.16%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
9
64
67
696
10
19
66
741
—
—
—
—
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
4.1e-01
1.7e+00
—
—
—
—
—
cases:10.53%
controls:7.24%
cases:15.79%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
8
55
68
705
12
24
64
736
—
—
—
—
—
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
5.6e-01
1.6e+00
—
1.0e+50
—
—
—
cases:17.11%
controls:10.53%
cases:19.74%
controls:4.74%
—
—
cases:9.21%
controls:0.00%
—
—
—
—
—
—
13
80
63
680
15
36
61
724
—
7
0
69
760
—
—
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.7e-01
1.4e+00
—
—
—
—
—
cases:9.21%
controls:7.89%
cases:13.16%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
7
60
69
700
10
27
66
733
—
—
—
—
—
Tissue Pathology biopsy report
66121-5 [40768804]
2.3e-02
1.3e+00
—
—
—
—
—
cases:13.16%
controls:12.89%
cases:14.47%
controls:4.21%
—
—
—
—
—
—
—
—
—
—
10
98
66
662
11
32
65
728
—
—
—
—
—
Outpatient Visit
OP [9202]
-2.9e-01
1.9e-01
4.7e-01
—
1.3e+00
—
—
cases:69.74%
controls:75.53%
cases:59.21%
controls:54.47%
cases:17.11%
controls:11.45%
—
—
cases:30.65%
controls:10.66%
—
—
—
—
53
574
23
186
45
414
31
346
13
87
63
673
—
19
81
43
679
—
—
Ophthalmology
18 [38004463]
4.4e-01
1.2e+00
—
—
—
—
—
cases:21.05%
controls:14.61%
cases:18.42%
controls:6.32%
—
—
—
—
—
—
—
—
—
—
16
111
60
649
14
48
62
712
—
—
—
—
—
betamethasone
S02BA07 [21605169]
—
1.0e+00
—
—
—
—
—
—
—
cases:7.89%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
6
23
70
737
—
—
—
—
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
0
8
76
752
0
11
76
749
—
—
—
—
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-6.2e-02
—
—
—
—
—
—
cases:6.58%
controls:6.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
53
71
707
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
2.5e-01
—
—
—
—
—
—
cases:15.79%
controls:12.76%
—
—
—
—
—
—
—
—
—
—
—
—
12
97
64
663
—
—
—
—
—
—
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
acrivastine; oral
R06AX18 [21603518]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
ofloxacin
S01AE01 [43534856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Laceration/cut
S18 [2002000983]
1.6e-01
—
—
—
—
—
—
cases:10.53%
controls:9.08%
—
—
—
—
—
—
—
—
—
—
—
—
8
69
68
691
—
—
—
—
—
—
Spinalanesthesia
WX320 [2001310799]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
memantine; oral
N06DX01 [21604799]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
dabigatran etexilate; oral
B01AE07 [21601026]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Infectious Disease
44 [38004484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
24
76
736
—
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
1.0e+00
—
—
—
—
—
—
cases:7.89%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
6
23
70
737
—
—
—
—
—
—
Pelvis X-ray examination
NE1AA [2001307792]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Conjunctival surface anesthesia
WX100 [2001310764]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Partial excision of intracranial lesion
AAB10 [2001300257]
—
1.0e+50
—
—
1.0e+50
—
—
—
—
cases:9.21%
controls:0.00%
—
—
—
—
cases:11.29%
controls:0.00%
—
—
—
—
—
7
0
69
760
—
—
7
0
55
760
—
—
chloramphenicol
S01AA01 [21603554]
8.7e-02
—
—
—
—
—
—
cases:10.53%
controls:9.74%
—
—
—
—
—
—
—
—
—
—
—
—
8
74
68
686
—
—
—
—
—
—
Striking against or struck by other object(s)
W22 [45756260]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Other specified urinary incontinence
N39.4 [45577525]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
3.2e-01
5.0e-01
—
—
—
—
—
cases:9.21%
controls:6.84%
cases:6.58%
controls:4.08%
—
—
—
—
—
—
—
—
—
—
7
52
69
708
5
31
71
729
—
—
—
—
—
prednisolone
A07EA01 [21600653]
3.1e-01
4.9e-01
—
—
-1.0e+50
—
—
cases:15.79%
controls:12.11%
cases:10.53%
controls:6.71%
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
12
92
64
668
8
51
68
709
—
—
0
6
62
754
—
—
Extensive health check-up at 4 months of age
SPAT1381 [2001700481]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
fluticasone; nasal
R01AD08 [21605050]
-3.6e-01
—
—
—
—
—
—
cases:7.89%
controls:10.92%
—
—
—
—
—
—
—
—
—
—
—
—
6
83
70
677
—
—
—
—
—
—
Corneal ulcer
H16.0 [45557339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
LC2DE [2001306545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
76
749
—
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
0
15
76
745
—
—
0
5
62
755
—
—
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
Norclozapine [Moles/volume] in Serum or Plasma
14851-0 [3008832]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
Urology
34 [38004474]
-1.0e-01
—
—
—
—
—
—
cases:6.58%
controls:7.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
55
71
705
—
—
—
—
—
—
Handing over of treatment supplies
SPAT1262 [2001700363]
3.2e-01
—
—
—
—
—
—
cases:6.58%
controls:4.87%
—
—
—
—
—
—
—
—
—
—
—
—
5
37
71
723
—
—
—
—
—
—
frovatriptan; oral
N02CC07 [21604382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
0.0e+00
—
—
—
—
—
—
cases:9.21%
controls:9.21%
—
—
—
—
—
—
—
—
—
—
—
—
7
70
69
690
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
-3.4e-01
—
—
—
-1.0e+50
—
—
cases:7.89%
controls:10.79%
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
6
82
70
678
—
—
—
0
5
62
755
—
—
amlodipine; oral
C08CA01 [21601747]
3.8e-01
4.1e-01
—
—
1.3e+00
—
—
cases:14.47%
controls:10.39%
cases:11.84%
controls:8.16%
—
—
—
—
cases:8.06%
controls:2.24%
—
—
—
—
11
79
65
681
9
62
67
698
—
—
5
17
57
743
—
—
pH of Arterial blood
2744-1 [3019977]
1.7e+00
—
—
—
1.0e+50
—
—
cases:9.21%
controls:1.84%
—
—
—
—
—
—
cases:16.13%
controls:0.00%
—
—
—
—
7
14
69
746
—
—
—
10
0
52
760
—
—
Recurrent depressive disorder, unspecified
F33.9 [45581458]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
Occupational health examination
Z10.0 [45581006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
latanoprost
S01EE01 [21603710]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
—
temozolomide
L01AX03 [21601419]
—
1.0e+50
—
—
—
—
—
—
—
cases:6.58%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
5
0
71
760
—
—
—
—
—
Gastroenterology
10 [38004455]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
0
5
62
755
—
—
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Paranoid schizophrenia continuous
F20.00 [2000501920]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.79%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
6
76
754
0
5
76
755
—
—
—
—
—
Pain in limb
M79.6 [45587063]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
-4.5e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:9.21%
controls:13.68%
—
—
cases:0.00%
controls:1.05%
—
—
cases:0.00%
controls:1.71%
—
—
—
—
7
104
69
656
—
0
8
76
752
—
0
13
62
747
—
—
Haemorrhoids, unspecified
K64.9 [45581909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Migraine
G43 [45566873]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Bacteria identified in Cerebral spinal fluid by Culture
606-4 [3016914]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:9.68%
controls:0.00%
—
—
—
—
—
—
—
—
6
0
56
760
—
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
3.6e-01
2.1e-01
—
—
—
—
—
cases:11.84%
controls:8.55%
cases:6.58%
controls:5.39%
—
—
—
—
—
—
—
—
—
—
9
65
67
695
5
41
71
719
—
—
—
—
—
Dorsalgia
M54 [45553203]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
76
745
—
—
—
—
—
—
nitrofurantoin; oral
J01XE01 [21603058]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
—
0
13
76
747
—
—
—
—
—
Gout
M10 [45533711]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
0
16
76
744
0
5
76
755
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.71%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
13
76
747
0
9
76
751
—
—
—
—
—
Depressive episode, unspecified
F32.9 [45571760]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
76
741
—
—
—
—
—
—
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Other minor procedure in surgery of teeth, jaws, mouth and pharynx
TEW99 [2001302349]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
76
744
—
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
-1.6e-02
—
—
—
—
—
—
cases:9.21%
controls:9.34%
—
—
—
—
—
—
—
—
—
—
—
—
7
71
69
689
—
—
—
—
—
—
dexbrompheniramine, combinations
R06AB56 [21603469]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.58%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
12
76
748
0
7
76
753
—
—
—
—
—
ketotifen
S01GX08 [21605092]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
9
76
751
0
7
76
753
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.71%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
13
76
747
0
7
76
753
—
—
—
—
—
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:9.68%
controls:0.00%
—
—
—
—
—
—
—
—
6
0
56
760
—
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
5.4e-01
1.9e+00
—
—
—
—
—
cases:7.89%
controls:4.74%
cases:6.58%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
6
36
70
724
5
8
71
752
—
—
—
—
—
Simple examination of mouth
SAA01 [2001310274]
9.8e-02
5.9e-02
—
—
—
—
—
cases:28.95%
controls:26.97%
cases:13.16%
controls:12.50%
—
—
—
—
—
—
—
—
—
—
22
205
54
555
10
95
66
665
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
-1.3e-01
—
—
—
-1.0e+50
—
—
cases:14.47%
controls:16.18%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
11
123
65
637
—
—
—
0
7
62
753
—
—
Allergy, unspecified
T78.4 [45580373]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
vortioxetine; oral
N06AX26 [44819158]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
76
745
—
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
-1.2e-01
-9.6e-02
1.5e+00
—
—
—
—
cases:36.84%
controls:39.61%
cases:15.79%
controls:17.11%
cases:6.58%
controls:1.58%
—
—
—
—
—
—
—
—
28
301
48
459
12
130
64
630
5
12
71
748
—
—
—
—
Intraoral radiographic dental examination
EB1AA [2001301903]
1.8e-01
—
—
—
—
—
—
cases:19.74%
controls:16.97%
—
—
—
—
—
—
—
—
—
—
—
—
15
129
61
631
—
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
5.6e-01
—
—
—
—
—
—
cases:10.53%
controls:6.32%
—
—
—
—
—
—
—
—
—
—
—
—
8
48
68
712
—
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
3.7e-01
5.8e-01
—
—
-1.0e+50
—
—
cases:19.74%
controls:14.47%
cases:10.53%
controls:6.18%
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
15
110
61
650
8
47
68
713
—
—
0
10
62
750
—
—
insulin aspart; parenteral
A10AD05 [21600733]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.1e+00
—
—
1.0e+50
—
—
—
cases:7.89%
controls:2.89%
—
—
—
—
cases:18.42%
controls:0.00%
—
—
—
—
—
—
6
22
70
738
—
—
14
0
62
760
—
—
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
3.5e-01
—
—
—
—
—
—
cases:6.58%
controls:4.74%
—
—
—
—
—
—
—
—
—
—
—
—
5
36
71
724
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
76
748
—
—
—
—
—
—
Chronic gingivitis
K05.18 [2000502721]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
—
—
Neoplasm of uncertain or unknown behaviour: Kidney
D41.0 [45581311]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
hydrocortisone buteprate
D07AB11 [21602115]
8.1e-02
6.5e-01
—
—
—
—
—
cases:9.21%
controls:8.55%
cases:6.58%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
7
65
69
695
5
27
71
733
—
—
—
—
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
4.9e-01
—
—
—
—
—
—
cases:15.79%
controls:10.26%
—
—
—
—
—
—
—
—
—
—
—
—
12
78
64
682
—
—
—
—
—
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
Need for immunization against influenza
Z25.1 [45581017]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Bone marrow biopsy
XW000 [2001310618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10351-5 [3013180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:11.29%
controls:0.00%
—
—
—
—
—
—
—
—
7
0
55
760
—
—
donepezil; oral
N06DA02 [21604795]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
Dysuria/painful urination
U01 [2002001137]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Examination and observation for other specified reasons
Z04.8 [45552063]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Oxygen content in Capillary blood by calculation
64799-0 [40767503]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Prostate cancer
116 [2001600116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Single live birth
Z37.0 [45571346]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Monitoring of emergency patient
SPAT1104 [2001700205]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
nystatin; vaginal
G01AA01 [21602363]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Other administrative function
SPAT1281 [2001700382]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
-2.5e-01
-4.3e-01
-1.0e+50
—
-1.0e+50
—
—
cases:19.74%
controls:24.08%
cases:13.16%
controls:18.95%
cases:0.00%
controls:2.76%
—
—
cases:0.00%
controls:1.97%
—
—
—
—
15
183
61
577
10
144
66
616
0
21
76
739
—
0
15
62
745
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
-1.4e-01
-4.7e-02
—
—
—
—
—
cases:32.89%
controls:36.05%
cases:21.05%
controls:21.84%
—
—
—
—
—
—
—
—
—
—
25
274
51
486
16
166
60
594
—
—
—
—
—
Risk factor NOS
A23 [2002000158]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:11.29%
controls:0.00%
—
—
—
—
—
—
—
—
7
0
55
760
—
—
Cathetrisation of vein
TPH04 [2001309597]
7.0e-01
1.8e+00
—
1.0e+50
—
—
—
cases:7.89%
controls:4.08%
cases:7.89%
controls:1.45%
—
—
cases:9.21%
controls:0.00%
—
—
—
—
—
—
6
31
70
729
6
11
70
749
—
7
0
69
760
—
—
—
Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Primary coxarthrosis, bilateral
M16.0 [45543482]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
tadalafil; oral
G04BE08 [21602653]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
—
roxithromycin; oral
J01FA06 [21602974]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Acute vaginitis
N76.0 [45543891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-1.5e-01
1.5e-01
—
—
—
—
—
cases:32.89%
controls:36.32%
cases:23.68%
controls:21.05%
—
—
—
—
—
—
—
—
—
—
25
276
51
484
18
160
58
600
—
—
—
—
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.58%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
12
76
748
0
7
76
753
—
—
—
—
—
Tension-type headache
G44.2 [45581495]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
scopolamine
A04AD01 [21600499]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.58%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
12
76
748
0
7
76
753
—
—
—
—
—
mirtazapine; oral
N06AX11 [21604740]
4.5e-01
1.2e+00
2.2e+00
—
—
—
—
cases:9.21%
controls:6.05%
cases:10.53%
controls:3.42%
cases:6.58%
controls:0.79%
—
—
—
—
—
—
—
—
7
46
69
714
8
26
68
734
5
6
71
754
—
—
—
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
moxonidine; oral
C02AC05 [21600401]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.32%
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
0
10
76
750
0
8
76
752
—
—
—
—
—
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
76
737
—
—
—
—
—
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
8.6e-01
1.1e+00
—
—
—
—
—
cases:6.58%
controls:2.89%
cases:6.58%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
5
22
71
738
5
18
71
742
—
—
—
—
—
pramipexole; oral
N04BC05 [21604477]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.58%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
12
76
748
0
9
76
751
—
—
—
—
—
Acromioplastia, arthroscopic
NBG15 [2001307302]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Therapeutic discussion
SPAT1240 [2001700341]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.50%
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
0
19
76
741
0
10
76
750
—
—
—
—
—
acetylcysteine; inhalant, oral
R05CB01 [21603380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
apixaban; oral
B01AF02 [43534762]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Chest symptom/complaint
L04 [2002000629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Cytology report of Cervical or vaginal smear or scraping Cyto stain
47528-5 [3050380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
4.2e-01
—
—
—
—
—
—
cases:13.16%
controls:9.08%
—
—
—
—
—
—
—
—
—
—
—
—
10
69
66
691
—
—
—
—
—
—
Body height measure
50373000 [4177340]
-6.1e-01
5.7e-01
—
—
—
—
—
cases:13.16%
controls:21.84%
cases:13.16%
controls:7.89%
—
—
—
—
—
—
—
—
—
—
10
166
66
594
10
60
66
700
—
—
—
—
—
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
—
1.2e+00
—
—
—
—
—
—
—
cases:7.89%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
6
19
70
741
—
—
—
—
—
Right side
ZXA00 [2001311346]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
76
749
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
0
11
76
749
—
—
—
—
—
Bacteria identified in Urine by Culture
630-4 [3026008]
5.6e-01
—
—
—
—
—
—
cases:10.53%
controls:6.32%
—
—
—
—
—
—
—
—
—
—
—
—
8
48
68
712
—
—
—
—
—
—
Enzyme measurement
122444009 [4046263]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
acetylcysteine
V03AB23 [21605248]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.7e+00
—
—
—
1.0e+50
—
—
cases:6.58%
controls:1.32%
—
—
—
—
—
—
cases:8.06%
controls:0.00%
—
—
—
—
5
10
71
750
—
—
—
5
0
57
760
—
—
Left side
ZXA05 [2001311347]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
Retained dental root
K08.3 [45543292]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Chronic periodontitis
K05.3 [45586694]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-1.2e-01
-9.6e-02
1.5e+00
—
—
—
—
cases:36.84%
controls:39.61%
cases:15.79%
controls:17.11%
cases:6.58%
controls:1.58%
—
—
—
—
—
—
—
—
28
301
48
459
12
130
64
630
5
12
71
748
—
—
—
—
Back symptom/complaint
L02 [2002000627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
norethisterone; oral
G03DC02 [21602553]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Hip X-ray examination
NF1AA [2001307894]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
76
750
—
—
—
—
—
—
Cytology report of Urine Cyto stain
47525-1 [3049717]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.7e+00
—
—
1.0e+50
—
—
—
cases:6.58%
controls:1.32%
—
—
—
—
cases:7.89%
controls:0.00%
—
—
—
—
—
—
5
10
71
750
—
—
6
0
70
760
—
—
—
miconazole
D01AC02 [21601921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Periodontal treatment
SDA03 [2001310328]
-3.2e-01
8.7e-01
-1.0e+50
—
—
—
—
cases:6.58%
controls:8.82%
cases:9.21%
controls:4.08%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
5
67
71
693
7
31
69
729
0
5
76
755
—
—
—
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
76
747
—
—
—
—
—
—
brompheniramine, combinations
R06AB51 [21603466]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
hydrocortisone butyrate
D07AB02 [21602106]
8.1e-02
6.5e-01
—
—
—
—
—
cases:9.21%
controls:8.55%
cases:6.58%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
7
65
69
695
5
27
71
733
—
—
—
—
—
Alkaline phosphatase.liver 1 [Enzymatic activity/volume] in Serum or Plasma
13874-3 [3035062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
1.3e-01
4.9e-01
—
—
—
—
—
cases:23.68%
controls:21.45%
cases:11.84%
controls:7.63%
—
—
—
—
—
—
—
—
—
—
18
163
58
597
9
58
67
702
—
—
—
—
—
Functional diarrhoea
K59.1 [45543327]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
4.3e-01
—
—
—
—
—
—
cases:11.84%
controls:8.03%
—
—
—
—
—
—
—
—
—
—
—
—
9
61
67
699
—
—
—
—
—
—
X-ray mammography
HA1AA [2001303884]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
-6.1e-02
—
-1.0e+50
—
-1.0e+50
—
—
cases:9.21%
controls:9.74%
—
—
cases:0.00%
controls:1.18%
—
—
cases:0.00%
controls:0.66%
—
—
—
—
7
74
69
686
—
0
9
76
751
—
0
5
62
755
—
—
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
2.0e+00
—
—
—
—
—
—
—
cases:6.58%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
5
7
71
753
—
—
—
—
—
Other senile cataract
H25.8 [45605644]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Venereal disease screening
171128005 [4064905]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Human epididymis protein 4 [Moles/volume] in Serum or Plasma
55180-4 [40758310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
-5.2e-01
—
—
—
—
—
—
cases:9.21%
controls:14.61%
—
—
—
—
—
—
—
—
—
—
—
—
7
111
69
649
—
—
—
—
—
—
hydrocortisone
D07AA02 [21602102]
8.1e-02
6.5e-01
—
—
—
—
—
cases:9.21%
controls:8.55%
cases:6.58%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
7
65
69
695
5
27
71
733
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
-2.0e-01
—
—
—
—
—
—
cases:6.58%
controls:7.89%
—
—
—
—
—
—
—
—
—
—
—
—
5
60
71
700
—
—
—
—
—
—
doxepin; oral, parenteral
N06AA12 [21604699]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
candesartan and diuretics
C09DA06 [21601838]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.32%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
0
10
76
750
0
5
76
755
—
—
—
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
7.8e-01
—
—
—
—
—
—
cases:15.79%
controls:7.89%
—
—
—
—
—
—
—
—
—
—
—
—
12
60
64
700
—
—
—
—
—
—
Chronic kidney disease, unspecified
N18.9 [45553438]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
Dental examination
Z01.2 [45581002]
-1.1e-01
4.7e-01
—
—
—
—
—
cases:9.21%
controls:10.13%
cases:6.58%
controls:4.21%
—
—
—
—
—
—
—
—
—
—
7
77
69
683
5
32
71
728
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
2.6e-01
1.4e+00
—
1.0e+50
—
—
—
cases:14.47%
controls:11.58%
cases:11.84%
controls:3.16%
—
—
cases:6.58%
controls:0.00%
—
—
—
—
—
—
11
88
65
672
9
24
67
736
—
5
0
71
760
—
—
—
Pregnancy
W78 [2002001269]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
0
5
62
755
—
—
cromoglicic acid
S01GX01 [21605085]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
Provision of consultation response
SPAT1285 [2001700386]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
Incomplete uterovaginal prolapse
N81.2 [45596883]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Polyp of corpus uteri
N84.0 [45596887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Assessment of need for medical rehabilitation
SPAT1215 [2001700316]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
nystatin
D01AA01 [21601911]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Otitis externa, unspecified
H60.9 [45605727]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
0.0e+00
—
—
—
—
—
—
cases:6.58%
controls:6.58%
—
—
—
—
—
—
—
—
—
—
—
—
5
50
71
710
—
—
—
—
—
—
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Iron deficiency anaemia, unspecified
D50.9 [45605373]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
loratadine; oral
R06AX13 [21603514]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.50%
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
0
19
76
741
0
8
76
752
—
—
—
—
—
Tinea unguium
B35.1 [45590850]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
8
76
752
0
5
76
755
—
—
—
—
—
Red eye
F02 [2002000400]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
76
751
—
—
—
—
—
—
Parkinson disease
G20 [45538098]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
76
754
—
—
—
—
—
—
Ultrasound measurement of residual urine
KC1EE [2001305918]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
76
746
—
—
—
—
—
—
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
-9.3e-03
-1.0e+50
-1.0e+50
—
—
—
—
cases:17.11%
controls:17.24%
cases:0.00%
controls:4.47%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
13
131
63
629
0
34
76
726
0
6
76
754
—
—
—
—
Polyarthrosis
M15 [45596490]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Sprain and strain of ankle
S93.4 [45550848]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
76
752
—
—
—
—
—
—
hydrocortisone
A07EA02 [21600654]
6.5e-02
6.5e-01
—
—
—
—
—
cases:9.21%
controls:8.68%
cases:6.58%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
7
66
69
694
5
27
71
733
—
—
—
—
—
Plantar fascial fibromatosis
M72.2 [45553265]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
—
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
0
8
76
752
0
7
76
753
—
—
—
—
—
Emergency treatment
SGA01 [2001310379]
9.6e-01
—
—
—
—
—
—
cases:6.58%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
—
—
5
20
71
740
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
-3.7e-01
2.2e-01
-1.0e+50
—
-1.0e+50
—
—
cases:7.89%
controls:11.05%
cases:9.21%
controls:7.50%
cases:0.00%
controls:1.58%
—
—
cases:0.00%
controls:1.18%
—
—
—
—
6
84
70
676
7
57
69
703
0
12
76
748
—
0
9
62
751
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
7
76
753
—
—
—
—
—
Other chronic pain
R52.2 [45568139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
76
755
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
4.7e-01
4.7e-01
—
—
—
—
—
cases:10.53%
controls:6.84%
cases:6.58%
controls:4.21%
—
—
—
—
—
—
—
—
—
—
8
52
68
708
5
32
71
728
—
—
—
—
—
Heart failure, unspecified
I50.9 [45576879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
76
746
—
—
—
—
—
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
0
9
76
751
0
5
76
755
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
81
6.67
15.02
17.6
7.8
7.42
7.41
ph
0.05
18
44
34
81
6.67
15.02
17.5
7.8
1.32
0.98
mmol/l
0.20
26
69
27
59
6.47
12.83
1.5
1.3
—
—
—
0
0
15
10
18.18
9.99
2.9
1.9
—
—
—
0
0
43
176
4.22
9.12
5.0
4.8
—
—
—
0
0
14
15
11.09
7.66
2.9
1.4
590.21
488.87
mg/l
0.30
14
15
31
115
3.81
7.28
4.4
2.8
144.00
440.89
ng/l
0.55
24
82
9
5
20.05
6.43
1.9
1.0
—
—
—
0
0
51
297
3.07
5.30
3.3
2.7
—
—
estimate
—
0
0
50
289
3.03
5.25
8.0
14.1
1.19
1.22
inr
0.14
43
238
18
57
3.81
5.15
36.5
17.5
24.28
25.28
mmol/l
0.60
18
57
12
20
6.88
5.15
5.6
6.5
307.43
138.58
mg/l
—
7
12
8
9
9.74
4.39
4.5
1.0
37.13
17.63
ug/l
—
8
9
38
204
2.68
4.37
2.9
2.5
—
—
—
0
0
26
119
2.78
4.02
9.6
5.0
0.81
0.81
mmol/l
0.02
26
111
14
40
4.04
3.85
13.8
2.6
—
—
—
0
0
11
280
0.29
3.75
3.2
3.1
—
—
—
0
0
15
53
3.27
3.59
24.6
10.3
95.51
93.01
%
1.11
15
53
6
6
10.69
3.56
1.8
1.5
20.82
14.67
ng/l
—
6
6
57
399
2.59
3.46
21.1
11.3
4.71
4.09
e9/l
0.30
51
346
6
7
9.15
3.32
2.2
2.3
—
—
—
0
0
5
5
10.55
3.02
1.0
1.2
279.00
260.20
mg/l
—
5
5
50
345
2.25
2.92
12.1
7.2
0.64
0.57
e9/l
1.04
43
300
50
346
2.24
2.89
12.3
7.3
0.04
0.04
e9/l
0.31
43
301
52
375
2.16
2.59
14.9
6.5
12.44
11.54
umol/l
0.18
52
356
31
184
2.14
2.57
3.9
3.0
—
—
—
0
0
50
358
2.10
2.50
14.1
7.4
0.16
0.19
e9/l
0.85
45
314
20
100
2.34
2.49
18.7
10.2
105.30
103.57
mmol/l
0.74
20
100
16
72
2.54
2.48
32.4
11.9
—
—
—
0
0
6
13
4.90
2.32
1.0
1.2
—
—
—
0
0
36
234
2.00
2.29
16.7
6.8
—
—
—
0
0
32
203
1.98
2.16
3.7
4.3
7.41
7.40
ph
0.84
24
138
5
10
5.26
2.10
1.0
1.2
—
—
—
0
0
5
10
5.26
2.10
1.2
1.8
41.10
41.05
%
—
5
10
36
252
1.80
1.72
2.7
2.0
—
—
—
0
0
12
56
2.35
1.71
4.8
2.5
10.78
10.18
g/l
0.10
12
46
16
86
2.08
1.65
1.7
1.5
—
—
—
0
0
67
729
0.43
1.59
52.4
23.7
131.75
136.91
g/l
2.22
67
721
67
729
0.43
1.59
56.8
24.4
39.33
40.84
%
2.24
67
720
67
729
0.43
1.59
51.8
23.5
90.50
90.68
fl
0.14
67
721
67
729
0.43
1.59
51.8
23.5
30.33
30.25
pg
0.15
67
721
0
33
0.00
1.19
0.0
1.2
—
0.90
—
0
33
0
34
0.00
1.19
0.0
1.2
—
0.69
—
0
8
28
202
1.60
1.11
1.4
1.5
—
—
—
0
0
11
60
1.97
1.09
29.4
7.9
7.41
7.42
ph
0.10
11
49
32
242
1.55
1.03
6.2
4.6
16.29
94.83
e6/l
1.36
17
169
66
707
0.57
0.87
42.9
19.4
66.80
78.27
umol/l
3.92
66
700
34
269
1.47
0.86
3.5
3.9
18.74
34.83
ng/l
1.18
28
188
10
160
0.57
0.85
3.2
6.7
—
—
—
0
0
0
24
0.00
0.80
0.0
1.0
—
5.80
—
0
11
0
26
0.00
0.80
0.0
1.0
—
5.57
—
0
16
27
208
1.46
0.77
5.3
3.8
10.40
49.17
e6/l
1.43
16
163
15
102
1.58
0.74
2.5
1.9
—
—
—
0
0
7
43
1.69
0.69
41.6
9.0
—
—
—
0
0
5
29
1.77
0.65
1.0
4.7
26.48
24.42
mmol/l
—
5
29
7
114
0.58
0.64
4.6
2.8
2.27
2.35
g/l
—
7
104
23
178
1.41
0.63
5.5
3.5
0.21
0.33
e6/l
0.31
13
132
8
52
1.60
0.62
19.8
11.5
25.00
24.72
mmol/l
—
8
52
0
21
0.00
0.61
0.0
1.0
—
1.82
—
0
11
22
170
1.41
0.60
5.2
3.4
—
—
estimate
—
0
0
24
192
1.36
0.54
3.9
4.1
3.09
7.96
mg/mmol
1.12
15
124
7
109
0.61
0.53
4.6
2.9
22.69
23.59
%
—
7
102
25
203
1.34
0.51
19.8
6.7
—
—
—
0
0
7
48
1.50
0.48
11.0
6.8
76.71
98.70
ng/l
—
7
41
35
301
1.30
0.47
3.6
3.7
6.34
6.13
ph
0.45
19
171
11
79
1.46
0.43
2.6
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
2.78
—
0
6
0
17
0.00
0.41
0.0
1.1
—
0.79
—
0
7
34
296
1.26
0.41
19.6
12.7
0.12
0.00
e9/l
0.49
27
236
9
66
1.41
0.40
5.1
4.3
6.98
8.57
ug/l
—
9
55
0
19
0.00
0.39
0.0
8.1
—
—
—
0
0
5
76
0.63
0.38
1.2
1.3
—
—
—
0
0
6
45
1.36
0.34
2.0
8.1
0.88
1.38
%
—
6
45
6
46
1.33
0.34
2.0
8.0
0.62
0.64
%
—
6
46
65
676
0.77
0.28
28.8
13.2
—
—
—
0
0
40
365
1.20
0.28
4.0
4.1
0.00
0.00
estimate
—
6
69
8
65
1.26
0.28
1.4
1.2
—
—
—
0
0
8
66
1.24
0.28
1.0
1.7
—
—
—
0
0
22
191
1.21
0.25
2.2
3.3
48.26
48.62
mg/l
0.00
15
128
6
83
0.70
0.25
1.8
1.2
—
—
—
0
0
5
40
1.27
0.23
1.2
3.6
4.86
4.65
pmol/l
—
5
34
39
361
1.16
0.21
4.1
4.1
0.00
0.00
estimate
—
6
69
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.5
—
9.00
—
0
11
0
11
0.00
0.21
0.0
2.5
—
4.96
—
0
11
0
11
0.00
0.21
0.0
3.5
—
32.91
—
0
11
0
11
0.00
0.21
0.0
1.0
—
0.29
—
0
5
0
10
0.00
0.21
0.0
2.0
—
9.59
—
0
10
0
10
0.00
0.21
0.0
2.8
—
16.80
—
0
10
0
12
0.00
0.21
0.0
5.0
—
15.09
—
0
12
0
13
0.00
0.21
0.0
1.0
—
0.32
—
0
5
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
6
48
1.27
0.21
2.8
2.1
6.00
6.15
ph
—
6
34
0
14
0.00
0.20
0.0
4.6
—
58.10
—
0
14
5
67
0.73
0.17
1.8
1.5
—
—
—
0
0
7
86
0.80
0.15
3.7
3.2
2.13
1.92
%
—
7
75
54
561
0.88
0.15
51.0
19.0
13.73
13.53
%
0.60
54
556
65
667
0.85
0.14
49.5
18.5
3.96
3.98
mmol/l
0.27
65
655
17
152
1.15
0.13
1.6
2.2
—
—
—
0
0
39
369
1.11
0.13
4.2
4.1
0.80
0.06
estimate
—
5
66
65
664
0.87
0.10
49.9
18.3
138.68
139.68
mmol/l
1.55
65
653
18
167
1.10
0.07
4.2
3.9
—
—
—
0
0
26
274
0.92
0.07
2.5
2.1
88.85
98.60
pmol/l
0.62
15
140
11
101
1.10
0.04
1.5
1.8
—
—
—
0
0
66
654
1.06
0.01
39.7
15.9
23.22
23.25
mg/l
0.00
66
535
12
126
0.94
0.01
1.3
1.8
—
—
—
0
0
22
218
1.01
0.00
3.9
3.6
—
—
—
0
0
12
123
0.97
0.00
1.3
1.7
466.29
114706347.05
pmol/l
—
7
102
49
492
0.99
0.00
3.6
4.6
15.76
14.81
pmol/l
1.13
49
454
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
7.49
—
0
5
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
120.67
—
0
6
0
8
0.00
-0.00
0.0
5.4
—
4.64
—
0
8
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
69.80
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
65
0.92
-0.00
1.0
1.3
—
—
—
0
0
7
75
0.93
-0.00
1.9
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
237.40
—
0
5
0
9
0.00
-0.00
0.0
3.8
—
0.80
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
272.76
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
91.41
—
0
8
0
5
0.00
-0.00
0.0
2.2
—
2279.00
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint G6_CEROEDEMA and mortality.

Females

Parameter HR [95% CI] p-value
G6_CEROEDEMA 9.279 [2.77, 31.05] < 0.001
Birth year 0.99 [0.98, 1.0] 0.032

During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 166 females with G6_CEROEDEMA died.

Males

Parameter HR [95% CI] p-value
G6_CEROEDEMA 10.985 [5.1, 23.68] < 0.001
Birth year 0.989 [0.98, 1.0] 0.023

During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 184 males with G6_CEROEDEMA died.

Mortality risk

Mortality risk for people of age

years, who have G6_CEROEDEMA.

N-year risk Females Males
1 0.852% 1.959%
5 4.155% 10.695%
10 11.262% 27.797%
15 21.457% 48.394%
20 33.987% 69.973%

Relationships between endpoints

↥

Index endpoint: G6_CEROEDEMA – Cerebral oedema

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data